ABSTRACT Objective: Determinants of the increased risk of diffuse large B-cell lymphoma (DLBCL) in SLE are unclear. Using data from a recent lymphoma genomewide association study (GWAS), we assessed whether certain lupus-related single nucleotide polymorphisms (SNPs) were also associated with DLBCL.
Several recent studies have highlighted an increased risk of haematological malignancies, particularly non-Hodgkin's lymphoma (NHL), in patients with SLE. 1 2 The determinants of the increased risk of NHL in SLE are unclear. The most common type of NHL in SLE (as in the general population) is the diffuse large B-cell lymphoma (DLBCL) subtype. Using data from a recent NHL genome-wide association study (GWAS), 3 our objective was to determine if certain SLE-related single nucleotide polymorphisms (SNPs) were also associated with the risk of DLBCL.
We focused on 28 SNPs independently associated with SLE in European Caucasians. 4 All of these SNPs have been strongly associated with lupus risk, with a p value of 1×10 −7 or stronger. Our hypothesis was that these SNPs would also be associated with DLBCL risk. For each SLE-related SNP, the ORs and 95% CIs were computed using a log-additive logistic regression model. Results from three previously conducted DLBCL GWAS studies were pooled in a random-effects meta-analysis. With 28 comparisons, an α of 0.05 would correspond to a Bonferroni-corrected p value of 0.0018. 5 In their assessment of genetic risk overlap between rheumatoid arthritis (RA) and haematological cancers, Okada et al 6 found that polymorphisms of TNFAIP3 were common to both RA and Hodgkin's lymphoma. Our analyses did not confirm a strong relationship with the lupus-related TNFAIP3 SNP rs7749323 specifically for DLBCL, but this may be a power issue, or may reflect the importance of different pathways for different haematological risk profiles across different autoimmune rheumatic diseases. Of note, our analyses were done in Caucasian populations; several non-Caucasian race/ethnic groups (eg, blacks, Asians) may have different genetic risk profiles and clinical presentations, thus future analyses could consider these populations as well. We have previously shown that the increased risk of lymphoma in SLE is similar across white, black and Asian patients. 7 In addition, it may be that specific genetic risk factors for different clinical SLE manifestations may drive some of the risk of lymphoma, although we were unable to investigate that hypothesis here.
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Existing data do suggest that some human leukocyte antigen (HLA) polymorphisms influence risk of DLBCL. 8 In recent DLBCL GWAS analyses, HLA-B 08-01 reached genome-wide significance. 4 In SLE, the strongest association in HLA is for the Class II allele DRB1*0301. This allele is in strong linkage disequilibrium with HLA-B*0801 in Caucasians so we are likely tagging the same HLA effect.
9 CD40, a member of the tumour necrosis superfamily, plays a central role in regulating immune cells; CD40 is expressed on several B-cell neoplasms including DLBCL. Data have suggested a possible role for functional polymorphisms (specifically, C vs T, rs1883832) in the TNFRSF5 gene encoding CD40 in lymphomas originating within the germinal centre (both DLBCL and follicular). 10 Tumour necrosis factor ligand superfamily involvement has been suggested in the pathology of malignant lymphomas. 11 Furthermore, in human NHL B-cell lines, IRF5 initiates a regulatory cascade by inducing the transcription factor activator protein 1 (AP-1) and cooperating with nuclear factor kappa B (NF-κB), which appears to represent a potentially important tumour promoting role of IRF5 in lymphoma. 12 Not all of the excess risk of haematological malignancies in SLE is necessarily due to genetic factors; exposures within the environment may also be at play. However, in the InterLymph Subtypes pooling project, autoimmune diseases as a risk for lymphoma appeared to be independent of other potentially shared environmental risk factors (body mass index, sun, alcohol, occupation, etc). 13 In the work of Ekström Smedby et al, SLE was associated with a 2.7-fold increase in risk of NHL risk overall; this was highest among patients with SLE of short duration (2-5 years), but a near twofold increase was also observed with more than 10 years of disease. Use of corticosteroid and immunosuppressive drugs categorically was not clearly linked to higher or lower risk, but analyses were not detailed. 2 Two very comprehensive case-control studies of SLE-related medications have suggested a link between cyclophosphamide (used intravenously in severe or resistant forms of SLE, especially nephritis) and haematological malignancies in general 14 (and specifically, in lymphoma 15 ). Fortunately, lymphoma after cyclophosphamide SLE treatment is a relatively uncommon outcome. Future studies of interactions between genetic factors and drug exposures may be warranted.
In conclusion, we studied a large GWAS datasets and found several plausible pathways linking DLBCL and SLE. Given that cyclophosphamide exposure in SLE is also associated with DLBCL risk, future studies might be able to explore whether these genetic risk factors may aid in risk stratification and decision-making when cyclophosphamide treatment is being considered for severe forms of SLE. 
